FDA Drug recall D-1090-2014
Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) Tablets, 30 Tablet Bottles, Rx only
- FDA Drug
- Class III
- terminated
- Published 2014-03-05
On 2014-03-05 the FDA classified a Class III recall of Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) Tablets, 30 Tablet Bottles, Rx only by Gilead Sciences, citing presence of Foreign Substance: Red Silicone Rubber Particulates are Present in Drug.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1090-2014 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2014-02-19 |
| Published | 2014-03-05 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Gilead Sciences |
| Distribution | US |
Product
Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) Tablets, 30 Tablet Bottles, Rx only. Manufactured for: Bristol-Myers Squibb & Gilead Sciences, LLC, Foster City, CA 94404. Made in Ireland. NDC 15584-0101-1. Manufactured for: Bristol-Myers-Squibb & Gilead Sciences, LLC, Foster City, CA 94404 Made in Ireland
Reason
Presence of Foreign Substance: Red Silicone Rubber Particulates are Present in Drug.
Identifiers
| code_info | Lot #'s: 002390, 002400, Exp 02/17. |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1090-2014%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.